MIT, MilliporeSigma create Pandemic Response CoLab
The Massachusetts Institute of Technology (MIT) has launched Pandemic Response CoLab with the goal of bringing together innovators from around the globe to solve problems associated with COVID-19.
Carmine, Takeda use extracellular vesicles for rare disease gene therapies
Carmine Therapeutics has signed a research collaboration agreement with Takeda Pharmaceutical to develop gene therapies for rare diseases.
Hoth Therapeutics, VCU partner on COVID-19 therapy
Hoth Therapeutics has inked a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential peptide COVID-19 treatment.
Avantor expands its innovation center for bioprocessing
Avantor is increasing its investment in bioprocessing infrastructure by expanding its innovation center in Bridgewater, NJ.
AGC Biologics expands plasmid manufacturing capacity
AGC Biologics is expanding its plasmid DNA Center of Excellence in Heidelberg, Germany, to meet the need for process development and manufacturing of plasmid DNA.
Ajinomoto introduces new drug manufacturing platform for COVID-19
Ajinomoto Bio-Pharma Services launched Ajility, a flexible drug product manufacturing platform for vaccines and therapies.
Marker Therapeutics expands cell therapy manufacturing
Marker Therapeutics plans to establish a new current good manufacturing practice manufacturing facility in Houston to support clinical development of multiantigen targeted-specific T-cell therapies.
ImmunoPrecise identifies SARS-CoV-2 neutralizing antibodies
ImmunoPrecise Antibodies has identified several lead candidate antibodies with high neutralizing activity in vitro that are being manufactured for further testing and possible inclusion in the company's PolyTope monoclonal antibody therapy against COVID-19.
Biocare Medical, Bethyl Laboratories partner for antibody development
Biocare Medical has formed a strategic partnership with Bethyl Laboratories to develop targeted antibodies for cancer research.
RevImmune initiates phase II study for COVID-19 immunotherapy
RevImmune has launched a phase II clinical trial of CYT107 immune therapy for treatment of COVID-19 and is preparing to expand to the U.S.